000516.SZ
国际医学
SZSE · Healthcare · Q 卫生 · CN
CNY 4.09
−2.39%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.0B | 4.1B | 4.8B | 4.6B | 2.7B |
| Cost of Revenue | 3.7B | 3.7B | 4.4B | 4.2B | 2.9B |
| Gross Profit | 381.0M | 336.4M | 455.1M | 440.8M | (178.0M) |
| Operating Expenses | |||||
| R&D Expense | 7.8M | 7.6M | 7.0M | 9.8M | 15.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 492.7M | 518.4M | 540.1M | 628.0M | 624.8M |
| Selling & Marketing Expense | 59.8M | 51.6M | 36.8M | 41.4M | 27.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 760.0M | 785.8M | 820.6M | 964.7M | 894.5M |
| Cost and Expenses | 4.4B | 4.5B | 5.2B | 5.1B | 3.8B |
| Operating Income (EBIT) | (342.7M) | (400.4M) | (342.2M) | (462.0M) | (1.1B) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (340.8M) | (400.3M) | (344.6M) | (467.3M) | (1.1B) |
| Income Tax Expense | 21.0M | 20.7M | 20.5M | 4.7M | 55.0M |
| Bottom Line | |||||
| Net Income | (255.1M) | (313.1M) | (254.1M) | (368.4M) | (1.2B) |
| Earnings from Cont. Ops | (361.7M) | (421.0M) | (365.1M) | (554.9M) | (995.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (255.1M) | (313.1M) | (254.1M) | (368.4M) | (1.2B) |
| Per Share | |||||
| Basic EPS | (CN¥0.11) | (CN¥0.14) | (CN¥0.11) | (CN¥0.16) | (CN¥0.52) |
| Diluted EPS | (CN¥0.11) | (CN¥0.14) | (CN¥0.11) | (CN¥0.16) | (CN¥0.43) |
| Revenue Per Share | CN¥1.81 | CN¥1.82 | CN¥2.08 | CN¥2.01 | CN¥1.20 |
| Shares | |||||
| Basic Shares Outstanding | 2.2B | 2.2B | 2.3B | 2.3B | 2.3B |
| Diluted Shares Outstanding | 2.2B | 2.2B | 2.3B | 2.3B | 2.3B |
| Profitability Metrics | |||||
| EBITDA | — | 304.7M | 403.0M | 321.8M | (499.3M) |
| D&A | — | 705.1M | 745.2M | 783.8M | 633.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026